Chandra, S., Nymeyer, A. C., Rice, P. F., Gerner, E. W., & Barton, J. K. (2017). Intermittent Dosing with Sulindac Provides Effective Colorectal Cancer Chemoprevention in the Azoxymethane-Treated Mouse Model. Cancer prevention research (Philadelphia, Pa.), 10(8), 459-466.
Sulindac is an NSAID that can provide effective chemoprevention for colorectal cancer. In this study, alternative dosing regimens of sulindac were evaluated for their chemoprevention effectiveness in the azoxymethane-treated A/J mouse model of colorectal cancer. High-resolution endoscopic optical coherence tomography was utilized to time-serially measure tumor number and tumor burden in the distal colon as the biological endpoints. Four treatment groups were studied: (i) daily for 20 weeks (sulindac-daily); (ii) for 2 weeks, then no sulindac for 2 weeks, cycle repeated 5 times (sulindac-2); (iii) for 10 weeks ("on"), then no sulindac for 10 weeks ("off"; sulindac-10); and (iv) no sulindac (sulindac-none). Sulindac-2 and sulindac-daily had statistically significantly lower final tumor counts and slopes (change in number of tumors per week) when compared with sulindac-none (P 0.0001). All of the treatment groups had statistically significantly lower final tumor burdens and slopes when compared with sulindac-none (P 0.001). There was a prolonged latency period in the sulindac-10 group, with no significant difference between the "off" portion of this treatment and sulindac-none. These results suggest that, although daily doses of sulindac provide the most optimal effects, intermittent doses of sulindac in a 50% duty cycle with an overall 4-week period (sulindac-2 model) can provide highly effective chemoprevention of colorectal cancer in this model. After cessation of sulindac treatment (sulindac-10 "off"), there is no evidence of either a persistent chemopreventive effect or a rebound effect. Cancer Prev Res; 10(8); 459-66. ©2017 AACR.
Barton, J. K., Barton, J. K., Marion, S. L., Rice, P. F., Utzinger, U., Brewer, M. A., Hoyer, P. B., & Barton, J. K. (2013). Two-photon excited fluorescence imaging of endogenous contrast in a mouse model of ovarian cancer. Lasers in surgery and medicine, 45(3).
Ovarian cancer has an extremely high mortality rate resulting from poor understanding of the disease. In order to aid understanding of disease etiology and progression, we identify the endogenous fluorophores present in a mouse model of ovarian cancer and describe changes in fluorophore abundance and distribution with age and disease.
Barton, J. K. (2007). Biophotonics - Big images small features. NATURE PHOTONICS, 1(12), 683-685.
Tate, T., Baggett, B., Rice, P., Watson, J., Orsinger, G., Nymeyer, A. C., Welge, W. A., Keenan, M., Saboda, K., Roe, D. J., Hatch, K., Chambers, S., Black, J., Utzinger, U., & Barton, J. (2015). Multispectral fluorescence imaging of human ovarian and Fallopian tube tissue for early stage cancer detection. ADVANCED BIOMEDICAL AND CLINICAL DIAGNOSTIC AND SURGICAL GUIDANCE SYSTEMS XIII, 9313.
Winkler, A. M., Rice, P., Weichsel, J., Watson, J. M., Backer, M. V., Backer, J. M., & Barton, J. K. (2011). In Vivo, Dual-Modality OCT/LIF Imaging Using a Novel VEGF Receptor-Targeted NIR Fluorescent Probe in the AOM-Treated Mouse Model. MOLECULAR IMAGING AND BIOLOGY, 13(6), 1173-1182.
